KRIBIOLISA™ Certolizumab pegol (CIMZIA) Inhibition ELISA

SKU: KBI1060 Category:

66,000.00

Enzyme Immunoassay for the estimation of Certolizumab pegol (CIMZIA) Inhibition in serum and plasma.

Key features:
1. Developed using highly specific monoclonal anti-idiotypic antibodies in a sandwich assay format
2. Validated as per international bioassay validation guidelines
3. Recovery: 80-120%
4. Precision CV <10%


Availability: 3 – 4 Weeks | Pack Size: 1 x 96 wells



Description

Background:
Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as E. coli. It was developed and manufactured by UCB Pharma, first FDA approved in 200813 and updated for a new indication on March 28, 2019.

Intended Use:
For Estimation of Certolizumab pegol (CIMZIA) Inhibition in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.

If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!

View more details about our Publication Reward

Additional information

Calibration Range

0 ng/ml – 640 ng/ml

Sensitivity

Limit of Quantification: 8 ng/ml Limit Of Detection: 7.75 ng/ml

Detection Method

Colorimetric

Specificity

80% – 120% to Certolizumab pegol (CIMZIA) Inhibition

Cross Reactivity

< 0.5% cross-reactivity observed with related biomarker.

Interference

No significant interference observed with available related molecules.

Storage Temprature

Store the unopened product at 2-8 Degree Celcius. Concentrated detection conjugate should be stored at -20 Degree Celcius. Do not use past expiration date.

Shipping Temperature

2-8 Degree Celcius. Concentrated detection conjugate ship at -20 Degree Celcius in a second box. Freight applicable for both.

Regulatory Status

Research Use Only

Research Area

Biosimilars / Therapeutic Drug Monitoring

Entez Gene ID

CDP 870 Human

Alternate Names / Synonyms

Certolizumab pegol

Alternate Drug Brand Names

Cimzia

Drug Bank Accession Number

DB08904

ELISA Type

Direct Sandwich Assay